Ambros Therapeutics launches with $125M to advance neridronate, a non-opioid therapy for CRPS-1. See how this Phase 3-ready ...
Biohaven didn't receive the clinical readout it was hoping for over the festive period. | As the biopharma wound down for the ...
MedPage Today on MSN
For Your Patients: How to Decide if a Clinical Trial Is Right for You
To be accepted into a clinical trial, all potential participants must meet the "eligibility criteria" by having similar ...
Two replicate phase 3 trials of GB-0895, an anti-thymic stromal lymphopoietin antibody, are enrolling adults and adolescents ...
Ultragenyx Pharmaceutical has reported the failure of a pair of late-phase brittle bone disease trials, prompting the biotech to prepare to significantly reduce its spending.
The drug is not considered a cure, but results from clinical trials point to major advancement for a devastating cancer ...
First-ever fentanyl overdose prevention vaccine could save thousands of lives annually, with human trials beginning early ...
Ultragenyx Pharmaceutical Inc. sank after the company’s experimental drug for a rare genetic bone disease failed to meet the ...
EMA provided overall agreement with the proposed Phase 3 clinical trial of VCN-01 in combination with ...
With a pair of Phase III trial flops, Ultragenyx will explore cost reductions as analysts turn attention to an upcoming ...
CYB003/CYB004 clinical catalysts into 2026, $248M cash runway, equity raises risk, valuation optionality. Click for this CYBN ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback